Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. - Wikidata - wikimedia - TriplyDB

Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

http://www.wikidata.org/entity/Q45341679

about

The toxic effect of R350P mutant desmin in striated muscle of man and mouse Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathies Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population.Cardiac Magnetic Resonance Scar Imaging for Sudden Cardiac Death Risk Stratification in Patients with Non-Ischemic Cardiomyopathy Role of cardiac MRI in the assessment of nonischemic cardiomyopathies Computed Tomography and Cardiac Magnetic Resonance in Ischemic Heart Disease Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration Cardiac Resynchronization Therapy in Non-Ischemic Cardiomyopathy Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view Impairment of Excitation-Contraction Coupling in Right Ventricular Hypertrophied Muscle with Fibrosis Induced by Pulmonary Artery Banding TRPC3-GEF-H1 axis mediates pressure overload-induced cardiac fibrosis Late Gadolinium Enhancement in Patients with Nonischemic Dilated Cardiomyopathy.Influence of phase correction of late gadolinium enhancement images on scar signal quantification in patients with ischemic and non-ischemic cardiomyopathy.Role of Cardiac MR Imaging in Cardiomyopathies Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis.[Ventricular tachycardia : Treatment and prognostic significance].Predictors of serious arrhythmic events in patients with nonischemic heart failure.Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): Study protocol for a randomized controlled trial.Cardiac fibroblast in development and wound healing.Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance.Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction.T2 mapping and T2* imaging in heart failure Subclinical Myocardial Disease in Heart Failure Detected by CMR.Quantifying late gadolinium enhancement on CMR provides additional prognostic information in early risk-stratification of nonischemic cardiomyopathy: a cohort study.Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease.Progression of diffuse myocardial fibrosis assessed by cardiac magnetic resonance T₁ mapping.Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study.Stratification of the risk of sudden death in nonischemic heart failure.Left ventricular geometric remodeling in relation to non-ischemic scar pattern on cardiac magnetic resonance imaging.Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease.Tools for risk stratification of sudden cardiac death: a review of the literature in different patient populations Cardiac imaging in evaluating patients prone to sudden death Mechanisms involved in the beneficial effects of spironolactone after myocardial infarction.Pediatric heart failure: current state and future possibilities.Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).QRS fragmentation and sudden cardiac death in the obese and overweight Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study Prognostic impact of blood pressure response plus gadolinium enhancement in dilated cardiomyopathy.

P2860

Q24306660-079E54CC-AE4D-4B9D-847D-15357763644D Q26765173-0F09BD44-02ED-46AA-9F4D-BC1C9E7BA51E Q26767019-C60D7B42-820C-4301-AD4A-B24EDFE41329 Q26801712-FBA388B9-A681-4351-9C7D-888EB6E3F54F Q26998997-1128BEB1-1754-484F-8762-4A598179F0F7 Q28066080-E8AEC1DF-5905-459A-8DB4-A665D6AC0E49 Q28068468-933C1B24-C57D-4C00-B8D6-F42ADDA39C51 Q28075924-372CDC07-FAA4-4875-B3CF-FFBCB65D7920 Q28078687-7C30DE52-3443-4EC5-9B0C-B73099E60CD4 Q28079620-DA517AF9-C603-4828-9D6A-E7396607874C Q28469354-BC2403E0-2C13-4ACA-80B6-3FF213117808 Q28817018-3B2E12F4-2BC2-4D5B-98C6-F3E2C04857DE Q30251600-BF2DD56D-3FF9-4B7F-B49A-2B6291FAAB9D Q30278892-8AC1C2AE-9FC6-4151-AF83-A4354849408D Q30279246-7810A859-E39E-4E0F-8563-AB7851552589 Q30407667-D274F70A-A972-4734-A18A-6EA5ED3B68A7 Q33163466-A3A333A5-B730-4BFE-BAF9-55C9F1489CDF Q33167997-36C0EE5E-29ED-425D-B4EC-EF783A6DC718 Q33168179-918F45C7-6A14-4315-BC5E-25E2BD50B217 Q33639215-700A5425-4C3D-4217-B985-5D7207AEFF9D Q33711320-9FAD9891-2A1D-4691-A2CD-CDD701E1C838 Q33727302-C9754205-5AD4-48CD-B48E-6C6376F9C0D3 Q33844225-F8AC48B3-2D07-4CD2-AFB8-31E5CFAB5407 Q34040150-8E0B403A-9CD8-4347-AAB9-69798A9E5B15 Q34130016-1F90B8F9-3FF0-4056-A648-4737BD26512B Q34166007-9E24DE5E-6EC8-40E4-B575-26C0B8423717 Q34216754-CBEE81CB-BF92-4FDD-A46F-018B204E0944 Q34374909-5AC4349B-B5C6-4424-9476-D7EAD9A7F860 Q34387880-BCFB4BCD-6294-4E4E-A07C-70EAF68F7074 Q34518419-66FEDC81-CC51-4675-93E0-1CF042E9655E Q34531894-C6560B3A-8BAE-45E3-BC02-2A615718760E Q34541818-FF1D80C0-1965-487A-9C65-5C76AA5425ED Q34541844-521452B9-B092-450C-B21E-F7B556C8B8E3 Q35010403-0B8D8977-2010-4797-B760-5E0699589CAE Q35028584-F4F54CA3-390A-40B4-A46D-AB123301755A Q35181260-08FA0102-AB07-4000-A5D8-ECAF8597F007 Q35186659-F19FD327-C9CA-48F0-8B57-1259E289B16C Q35354217-6791A7F2-D3B3-4D5B-9FEA-00DE289DB303 Q35576188-13CCCEA1-D2E9-4BD1-9889-E44415EE4248 Q35605428-05CF6489-2496-4FFC-A4B5-E0B4586C6E85

P2860

Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

http://www.wikidata.org/entity/Q45341679

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Association of fibrosis with m ...... chemic dilated cardiomyopathy.

@en

Association of fibrosis with m ...... chemic dilated cardiomyopathy.

@nl

type

label

Association of fibrosis with m ...... chemic dilated cardiomyopathy.

@en

Association of fibrosis with m ...... chemic dilated cardiomyopathy.

@nl

prefLabel

Association of fibrosis with m ...... chemic dilated cardiomyopathy.

@en

Association of fibrosis with m ...... chemic dilated cardiomyopathy.

@nl

P1433

Q45341679-0715A789-4B39-48E4-9919-881854FF93B9

P1476

Q45341679-B3D52A81-5E44-4AB6-B8C9-8DF0E5834619

P2093

Q45341679-249E2F20-0EE5-4BFF-8FDF-F26BD823E4D0

Q45341679-2B7278B9-62B7-443A-A020-CF27712F977C

Q45341679-2BC3353E-2FA3-4653-A2DA-F8434E0FC9E4

Q45341679-2EC747A7-2A02-4814-9F28-89279BF7564D

Q45341679-566FF483-CBA3-48ED-B615-3B9F5B881EBA

Q45341679-6277D2E6-B3BF-4A58-AB09-BE3BB298FF7D

Q45341679-7A5491B2-5BBE-4E01-A1D7-E028E5E77878

Q45341679-8F88C261-B80E-4DBA-8C2A-06014FFF579F

Q45341679-93DFF250-88B7-41AD-8824-97567A0F951F

Q45341679-94C05D89-3253-4186-BA46-589FE8E8D57D

P304

Q45341679-2B685970-FA56-43C6-AAFF-6E445BEDDDF7

P31

Q45341679-E6CB8C51-9A07-4EA2-BFB4-45B3A666B124

P356

Q45341679-6E318FCC-8C0F-4612-97FE-5D5F5E917CD1

P407

Q45341679-5418F2C4-5EB0-4D78-98A3-A8EFC5EE0403

P433

Q45341679-7A01FF5D-1ED5-4C43-843B-19F33A94882E

P478

Q45341679-FDD66E51-6A89-413C-8FC9-0AB2C5AAE232

P50

Q45341679-21D378BE-5E6D-4157-A429-C6D5D8ECD5F9

Q45341679-538E5959-94FC-4D15-9A38-456C2F0E4FAE

Q45341679-72A0E00C-2633-44DA-89E1-E2134D736F6C

Q45341679-D44C8B87-916D-46CD-96F6-1306603B8FF3

P577

Q45341679-88150984-E23E-42E5-9DF8-643317CFBE75

P698

Q45341679-C30C9370-46C5-4870-AA9D-479D4E7C8AA9

P921

Q45341679-CE49514F-C56C-47BD-8843-BB3AD39E5528

P356

P1433

Journal of the American Medical Association

P1476

Association of fibrosis with m ...... chemic dilated cardiomyopathy.

@en

P2093

Alexander R Lyon

http://www.w3.org/2001/XMLSchema#string

Andrew Jabbour

http://www.w3.org/2001/XMLSchema#string

Ankur Gulati

http://www.w3.org/2001/XMLSchema#string

Elisa Di Pietro

http://www.w3.org/2001/XMLSchema#string

Francisco Alpendurada

http://www.w3.org/2001/XMLSchema#string

Jahanzaib Khwaja

http://www.w3.org/2001/XMLSchema#string

Kaushik Guha

http://www.w3.org/2001/XMLSchema#string

Kishen Morarji

http://www.w3.org/2001/XMLSchema#string

Michael Roughton

http://www.w3.org/2001/XMLSchema#string

Nizar A Ismail

http://www.w3.org/2001/XMLSchema#string

P304

896-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2013.1363

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

309

http://www.w3.org/2001/XMLSchema#string

P50

Mary N Sheppard

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23462786

http://www.w3.org/2001/XMLSchema#string

P921